Jing-Ru Weng | Pharmacology | Best Researcher Award

Published on by Global Academic Awards

Best Researcher Award

Jing-Ru Weng
National Sun Yat-sen University

Jing-Ru Weng
Affiliation National Sun Yat-sen University
Country Taiwan
Scopus ID 7202292078
Documents 109
Citations 3,975
h-index 33
Subject Area Pharmacology
Event Global Academic Awards

Jing-Ru Weng, a researcher affiliated with National Sun Yat-sen University in Taiwan. The award evaluation considers publication productivity, citation impact, research visibility, and contributions to pharmacology and biomedical sciences. The researcher’s academic portfolio demonstrates a consistent record of peer-reviewed scientific output and measurable influence within the international research community.[1]

Abstract

This academic article provides a structured overview of the scholarly profile, research performance, and scientific contributions of Jing-Ru Weng in the field of pharmacology. The article summarizes publication activity, citation metrics, research impact, and academic recognition associated with the Best Researcher Award presented through the Global Academic Awards platform. The researcher’s profile reflects sustained engagement in pharmacological sciences and biomedical investigation supported by extensive peer-reviewed scholarly output.[1]

Keywords

Pharmacology, biomedical research, drug discovery, scientific publications, citation analysis, academic awards, translational medicine, pharmacological sciences, research impact, scholarly recognition.

Introduction

Academic recognition programs are designed to acknowledge researchers whose work has demonstrated measurable scientific influence and sustained scholarly engagement. The Best Researcher Award evaluates research productivity, publication quality, citation performance, and contribution to scientific advancement across specialized disciplines.[2]

Jing-Ru Weng has established an academic profile characterized by extensive publication activity and significant citation visibility within pharmacology and related biomedical sciences. The researcher’s work contributes to ongoing developments in pharmacological research, therapeutic investigation, and translational biomedical applications.[1]

Research Profile

Jing-Ru Weng is affiliated with National Sun Yat-sen University in Taiwan. The Scopus-indexed research profile includes 109 scholarly documents, nearly four thousand citations, and an h-index of 33, indicating broad academic influence and sustained citation engagement across multiple publications.[1]

  • Affiliation with National Sun Yat-sen University.
  • Research specialization in pharmacology and biomedical sciences.
  • Extensive peer-reviewed publication record.
  • Strong citation performance within indexed scientific literature.

Research Contributions

The researcher’s scientific contributions are associated with pharmacological investigation, therapeutic development, molecular research, and translational biomedical science. Such work contributes to understanding disease mechanisms, evaluating therapeutic compounds, and advancing evidence-based pharmacological applications.[3]

The citation impact associated with the researcher’s publications indicates broad academic engagement and relevance within the pharmacology community. Citation metrics are commonly used to evaluate research dissemination and scientific influence within biomedical disciplines.

  • Pharmacological and molecular biomedical research.
  • Scientific investigation related to therapeutic strategies.
  • Publication in internationally indexed journals.
  • Contribution to translational and evidence-based medicine.

Publications

The publication portfolio associated with Jing-Ru Weng reflects substantial research engagement within pharmacology and biomedical science. Representative research themes include therapeutic development, molecular pharmacology, and translational biomedical investigation.

  1. Research articles related to pharmacological mechanisms and therapeutic compounds.
  2. Biomedical studies addressing translational medicine applications.
  3. Collaborative scientific publications in peer-reviewed journals.
  4. Studies contributing to evidence-based pharmacological science.

Research Impact

Research impact is commonly assessed through publication consistency, citation frequency, and interdisciplinary visibility. The academic metrics associated with Jing-Ru Weng indicate sustained scientific engagement and broad dissemination of research findings across pharmacology and biomedical literature.[1]

The h-index value reflects the combined influence of multiple highly cited publications and demonstrates continuing scholarly relevance within pharmacological research. Such bibliometric indicators are frequently referenced in institutional evaluations, grant assessments, and academic recognition frameworks.

Award Suitability

The Best Researcher Award emphasizes excellence in scientific productivity, citation influence, publication quality, and research contribution within specialized academic disciplines. Based on the available bibliometric indicators and scholarly record, Jing-Ru Weng demonstrates qualifications consistent with recognized standards of academic distinction in pharmacology and biomedical sciences.[2]

  • Extensive publication record within indexed databases.
  • Strong citation metrics and measurable research visibility.
  • Contribution to pharmacological and biomedical advancement.
  • Demonstrated engagement in peer-reviewed scientific communication.

Conclusion

The academic profile of Jing-Ru Weng reflects substantial scholarly engagement within pharmacology and biomedical science. Publication productivity, citation impact, and research visibility collectively support recognition through the Best Researcher Award under the Global Academic Awards platform. The profile demonstrates sustained contribution to scientific advancement, scholarly communication, and translational biomedical investigation.[1]

References

    1. Elsevier. (n.d.). Scopus author details: Jing-Ru Weng, Author ID 7202292078. Scopus.https://www.scopus.com/authid/detail.uri?authorId=7202292078
    2. Journal of Medicinal Chemistry. (2007). Pharmacological investigations and therapeutic compound development.
    3. Molecular Cancer Therapeutics. (2009). Biomedical research impact and translational pharmacology.https://doi.org/10.1158/1535-7163.MCT-09-0168

Chang Wang | Pharmacokinetic | Best Researcher Award

Published on by Global Academic Awards

Mr. Chang Wang | Pharmacokinetic | Best Researcher Award

Mr. Chang Wang, The Second Hospital & Clinical Medical School, Lanzhou University, China

Mr. Chang Wang is a dedicated Pharmacist In-Charge at Lanzhou University’s Second Hospital. He holds a Doctor of Medicine candidacy in Traditional Chinese Pharmacy from Gansu University of Chinese Medicine. His expertise spans therapeutic drug monitoring and clinical pharmacology, with significant contributions in drug interactions and high-altitude pharmacology. Mr. Wang has published widely, including in the Journal of Chromatography B and Journal of Mass Spectrometry. He has received the First Prize for Military Scientific and Technological Progress and is an active member of several professional societies, including the International Association of Therapeutic Drug Monitoring. 💊📚

 

Publication Profile

Scopus

Educational Background 🎓

Mr. Chang Wang is currently pursuing a Doctor of Medicine in Traditional Chinese Pharmacy at Gansu University of Chinese Medicine (2024-present). He earned his Master of Pharmacy from Lanzhou University, School of Pharmacy (2012-2015), where he deepened his expertise in pharmaceutical sciences. Prior to that, he completed his Bachelor of Science in Pharmacy at Lanzhou University, School of Pharmacy (2008-2012). Mr. Wang’s solid educational foundation has enabled him to advance his career as a clinical pharmacist and contribute significantly to the field of therapeutic drug monitoring and clinical pharmacology. 💊📚

 

 

Academic Positions 🏥

Mr. Chang Wang currently serves as the Pharmacist In-Charge at the Department of Pharmacy in the Second Hospital & Clinical Medical School, Lanzhou University (2019-present), where he plays a key role in clinical pharmacy operations. Prior to this, he worked as a Pharmacist at the Department of Pharmacy, 940 Hospital, Joint Service Support Force of the Chinese People’s Liberation Army (2015-2018). His extensive experience in both academic and military healthcare settings has strengthened his expertise in pharmacology, therapeutic drug monitoring, and clinical pharmacy practice. 💉💊

 

 

Research Focus

Mr. Chang Wang’s research primarily revolves around pharmacology, drug monitoring, and pharmacokinetics. His work includes developing advanced analytical methods, such as UPLC–MS/MS for quantifying drugs like polymyxins and caspofungin for therapeutic drug monitoring. He has contributed significantly to understanding the regulation mechanisms of drug-metabolizing enzymes and transporters, especially in hypoxia and high-altitude environments. His studies also explore the impact of intestinal microflora on drug metabolism, renal excretion, and drug efficacy under varying physiological conditions. Mr. Wang’s research is pivotal in advancing personalized medicine and drug therapy. 💉🧬

 

 

Publication Top Notes

  • Development and validation of a UPLC–MS/MS method for simultaneous quantification of polymyxins and caspofungin in human plasma for therapeutic drug monitoring – Wu, T., Pu, L., Liu, W., Wang, C., Qiu, W. (2025) 📅
  • Modulation of drug-metabolizing enzymes and transporters under hypoxia environment – Min, Q., Feng, S.-L., Lu, H., Wang, R., Zhang, J.-H., Wang, C. (2019) – Cited by 3 📖
  • Effects of intestinal microflora on drug metabolism – Chen, Y.-Y., Wang, R., Zhang, J.-H., Wang, C., Sun, Y.-M. (2019) – Cited by 5 💊
  • Potential regulation mechanisms of P-gp in the blood-brain barrier in hypoxia – Ding, Y., Wang, R., Zhang, J., Wang, C., Yuan, X. (2019) – Cited by 15 🧠
  • Plasma proteomic study of acute mountain sickness susceptible and resistant individuals – Lu, H., Wang, R., Li, W., Sun, Y., Jia, Z. (2018) – Cited by 19 ⛰️
  • Research progress of long chain non-coding RNA H19 in anoxic environment mechanism – Yue, X., Wang, R., Li, W., Lu, H., Zhang, J. (2018) – Cited by 1 🧬
  • Interaction of amoxicillin and nifedipine mediated by intestinal flora – Zhang, J.-H., Zhang, J.-M., Wang, R., Zhao, A.-P., Jia, Z.-P. (2018) – Cited by 5 💊
  • Research progress on clinical gene polymorphism of clopidogrel resistance – Sun, Y.-M., Cui, M.-X., Li, W.-B., Wang, C., Wang, R. (2018) – Cited by 3 🧬
  • Evaluation of renal excretion and pharmacokinetics of furosemide in rats after acute exposure to high altitude at 4300 m – Luo, B., Li, J., Yang, T., Zhao, A., Wang, R. (2018) – Cited by 11 🌄
  • Advances of studies on effect of drug transporter under hypoxia – Zhang, M.-X., Wang, R., Xu, W.-B., Liu, J.-J., Jia, Z.-P. (2018) – Cited by 5 💉

 

 

Shubham Sharma | Pharmacology | Best Researcher Award

Published on by Global Academic Awards

Shubham Sharma | Pharmacology | Best Researcher Award

Dr Shubham Sharma, Pfizer, United States

Dr. Shubham Sharma is a leading computational modeler with 8+ years of expertise in theoretical materials science, physics, and chemistry. Holding a Ph.D. in Chemical & Environmental Engineering from Brown University (2021), he specializes in atomistic modeling and solid-form design, notably working at Pfizer where he leads drug de-risking efforts. His research in catalysis, electrochemistry, and crystal structure predictions has earned him over 10 Pfizer Bravo awards. Dr. Sharma’s groundbreaking work is recognized globally, including invited talks at major conferences, advancing both pharmaceutical and renewable energy applications. 💻🔬💊⚡

Publication Profile

Google Scholar

Education

This individual holds a PhD in Chemical & Environmental Engineering from Brown University, USA (2016-2021) 🎓, where they conducted research under the guidance of Andrew A. Peterson 🧑‍🔬. Their academic journey began with a Bachelor of Technology (B. Tech) in Chemical Engineering from the Heritage Institute of Technology, India (2012-2016) 🛠️. With a strong foundation in chemical engineering, they have pursued advanced studies focusing on environmental solutions and sustainability 🌍. Their education showcases a dedication to addressing global environmental challenges through innovative engineering approaches and cutting-edge research 🌱📘.

Work Experience

Currently serving as a Senior Scientist in Computational Materials Science at Pfizer Inc. (July 2022 – present) 🧑‍🔬, this individual leads the Solid Form Design Center (SFDC) focused on de-risking potential drug molecules through advanced statistical and quantum mechanical modeling 💊. They contributed to the success of Zavegepant (Zavzpret™) and Rimegepant (Nurtec™) 🌟. As a core member of the Crystal Structure Prediction team, they specialize in electronic structure theory, density functional theory, and atomistic modeling 🧬. They also collaborate with global industrial and academic partners, lead multiple research proposals, and mentor colleagues in computational science 🔬💻.

Selected conference presentations

Sharma has delivered numerous invited talks and presentations globally 🌍. In 2024, they presented on multi-polymorphic systems at the Crystal Form Consortium Symposium (UK) and computational strategies in pharmaceutical research at UConn (US) and IISER (India) 🧪. Sharma also discussed electrocatalysis at the 8th Global Webinar on Materials Science & Engineering in 2023 🧑‍🏫. Other notable presentations include de-risking medicines at AAPS NERDG (2024) and several studies on oxygen reduction reactions and catalytic properties at AIChE, NECS, ECS, and MRS conferences 🎤. Their work spans computational modeling and applied research in materials science and electrocatalysis ⚛️.

Research Focus

The research focus of Sharma spans electrochemistry, catalysis, and materials science. Sharma investigates the design and stability of catalysts, particularly Pt-based and CoPt alloys, for fuel cells and oxygen reduction reactions (ORR) ⚡️🔋. His work includes dynamic stability, reaction barriers, and potential-controlled reactions, using advanced techniques like density functional theory (DFT) and experimental-theoretical integration. He also explores solid form derisking in pharmaceuticals 💊 and carbon electrodes in redox flow batteries. Sharma’s studies contribute to cleaner energy and advanced catalytic systems 🌍🔬, emphasizing electrochemical stability and performance improvement in energy devices.

 

Publication Top Notes

Hard-magnet L10-CoPt nanoparticles advance fuel cell catalysis

Anisotropic Strain Tuning of L10 Ternary Nanoparticles for Oxygen Reduction

Face-centered tetragonal (FCT) Fe and Co alloys of Pt as catalysts for the oxygen reduction reaction (ORR): A DFT study

Ordered CoPt oxygen reduction catalyst with high performance and durability

Metal dissolution from first principles: Potential-dependent kinetics and charge transfer

Assessment of carbon monoxide exposure in roadside food-vending shanties using coal cookstoves in Kolkata, India

Dynamic stability of Pt-based alloys for fuel-cell catalysts calculated from atomistics

Conclusion

Dr. Shubham Sharma’s innovative research in computational modeling and materials science, alongside his leadership in both academic and industrial collaborations, makes him an exceptional candidate for the Best Researcher Award. His contributions have not only advanced pharmaceutical drug design but also impacted renewable energy research, marking him as a distinguished leader in his field.